Skip to content
Triangle logo TriangleGet started
← Study library

NCT04394858 · CITED IN SOURCE DOCUMENTS

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2
Status at capture
ACTIVE NOT RECRUITING
Registry last update
2026-05-13

This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Poly (adenosine diphosphate \[ADP\]-ribose) polymerases (PARPs) are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib with temozolomide may shrink or stabilize the cancer in patients with pheochromocytoma or paraganglioma better than temozolomide alone.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: * Documentation of disease * Histologic documentation: Histologically-proven advanced (metastatic or unresectable primary) pheochromocytoma or paraganglioma * Stage: Advanced (metastatic or unresectable primary) disease * Tumor site: Histologically-proven pheochromocytoma or paraganglioma * Radiographic evaluation: Radiographic evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 in the 12 months prior to registration * Measurable disease * Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 1 cm with CT or MRI (or \>= 1.5 cm for lymph nodes). Non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung * Prior treatment with other somatostatin analog, chemotherapy, radiotherapy (including peptide radionuclide receptor therapy \[PRRT\]), or surgery must be completed \>= 28 days prior to registration. Patients must have recovered from any effects of any major surgery prior to registration * Prior treatment with radiolabeled metaiodobenzylguanidine (MIBG) must be completed \>= 12 weeks prior to registration and lifetime cumulative 131I-MIBG dose must be \< 1000 MBq kg\^-1 (36 mCi kg\^-1) * Prior treatment with antibiotics must be completed \>= 7 days prior to registration * No prior treatment with temozolomide, dacarbazine, or a poly ADP ribose polymerase (PARP) inhibitor * No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUCBT) * Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =\< 7 days prior to registration is required * Contraception * Therapy utilized in this trial is associated with medium/high fetal risk * Women of childbearing potential and their partners, who are sexually active, must agree to use two highly effective forms of contraception in combination. This should be started from the time of registration and continue throughout the period of taking study treatment and for at least 1 month after last dose of study drug(s), or they must totally/truly abstain from any form of sexual intercourse * Male patients must use a condom during treatment and for 3 months after the last dose of study drug(s) when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential. Male patients should not donate sperm throughout the period of taking study drug(s) and for 3 months following the last dose of study drug(s) * Age \>= 12 years * Eastern Cooperative Oncology Group (ECOG) Patients ≥ 18 years of age: Performance status: 0-2 * Patients \< 16 years of age: Lansky ≥ 50% * Patients 16 to \< 18 years of age: Karnofsky ≥ 50% * Patients ≥ 18 years of age: ECOG performance status ≤ 2 * Absolute neutrophil count \>= 1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Hemoglobin \>= 10 mg/dL if prior radionuclide therapy Hemoglobin \>= 8 mg/dL if no prior radionuclide therapy * In the absence of transfusion within the previous 24 hours. Radionuclide therapy includes PRRT or MIBG * Total bilirubin =\< 1.5 x upper limit of normal (ULN) * Except in the case of Gilbert's syndrome, then total bilirubin must be =\< 3.0 x ULN * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3.0 x ULN * Creatinine \< 1.5 x ULN OR calculated (calc.) creatinine clearance \> 50 mL/min * Calculated by Cockcroft-Gault equation * By Cockcroft-Gault equation. Alternatively, for patients \< 18 years of age, maximum serum creatinine ≤ the below age-sex-specific norms: * Age 12 years: Male 1.2; female 1.2 * Age 13 to \< 16 years: Male 1.5; female 1.4 * Age 16 to \< 18 years: Male 1.7; female 1.4 * No indication of uncontrolled, potentially reversible cardiac condition(s) as determined by investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's formula-corrected QT interval \[QTcF\] prolongation \> 500 msec, electrolyte disturbances, etc.) and no known congenital long QT syndrome * No extensive bilateral lung disease or pneumonitis * No abnormal organ or bone marrow function =\< 28 days prior to registration * Patients with human immunodeficiency virus (HIV) positivity are allowed if CD4 count \> 250 cells/uL and they have an undetectable HIV viral load within 6 months of registration * No active infection * No history of myelodysplastic syndrome (MDS) (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemia * No known gastrointestinal condition(s) that might predispose for drug intolerability or poor drug absorption * No known medical condition causing an inability to swallow oral formulations of agents * No history of allergic reaction attributed to compounds of similar chemical or biologic composition to PARP inhibitors * Concurrent use of combination antiretroviral therapy (ART) is not permitted * Chronic concomitant treatment with strong or moderate CYP3A4 inducers or inhibitors is not allowed. Patients must discontinue the agent(s) \>= 21 days prior to registration; enzalutamide and/or phenobarbital must be discontinued \>= 5 weeks prior to registration
healthy Volunteers
false
minimum Age
12 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive temozolomide PO QD and olaparib PO BID on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
    intervention Names
    1. Procedure: Biospecimen Collection
    2. Procedure: Computed Tomography with Contrast
    3. Procedure: Magnetic Resonance Imaging
    4. Drug: Olaparib
    5. Other: Quality-of-Life Assessment
    6. Drug: Temozolomide
    label
    Arm I (temozolomide, olaparib)
    type
    EXPERIMENTAL
  2. description
    Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
    intervention Names
    1. Procedure: Biospecimen Collection
    2. Procedure: Computed Tomography with Contrast
    3. Procedure: Magnetic Resonance Imaging
    4. Other: Quality-of-Life Assessment
    5. Drug: Temozolomide
    label
    Arm II (temozolomide)
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Arm I (temozolomide, olaparib)
    2. Arm II (temozolomide)
    description
    Undergo collection of blood samples
    name
    Biospecimen Collection
    other Names
    1. Biological Sample Collection
    2. Biospecimen Collected
    3. Sample Collection
    4. Specimen Collection
    type
    PROCEDURE
  2. arm Group Labels
    1. Arm I (temozolomide, olaparib)
    2. Arm II (temozolomide)
    description
    Undergo CT with contrast
    name
    Computed Tomography with Contrast
    other Names
    1. Contrast Enhanced Computed Tomography
    2. CONTRAST ENHANCED CT SCAN
    3. Contrast-enhanced Computed Tomography
    4. CT Scan With Contrast
    5. CT with Contrast
    type
    PROCEDURE
  3. arm Group Labels
    1. Arm I (temozolomide, olaparib)
    2. Arm II (temozolomide)
    description
    Undergo MRI
    name
    Magnetic Resonance Imaging
    other Names
    1. Magnetic Resonance
    2. Magnetic Resonance Imaging (MRI)
    3. Magnetic resonance imaging (procedure)
    4. Magnetic Resonance Imaging Scan
    5. Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    6. MR
    7. MR Imaging
    8. MRI
    9. MRI Scan
    10. MRIs
    11. NMR Imaging
    12. NMRI
    type
    PROCEDURE
  4. arm Group Labels
    1. Arm I (temozolomide, olaparib)
    description
    Given PO
    name
    Olaparib
    other Names
    1. AZD 2281
    2. AZD-2281
    3. AZD2281
    4. KU 0059436
    5. KU-0059436
    6. KU0059436
    7. Lynparza
    8. Olanib
    9. Olaparix
    10. PARP Inhibitor AZD2281
    type
    DRUG
  5. arm Group Labels
    1. Arm I (temozolomide, olaparib)
    2. Arm II (temozolomide)
    description
    Ancillary studies
    name
    Quality-of-Life Assessment
    other Names
    1. Quality of Life Assessment
    type
    OTHER
  6. arm Group Labels
    1. Arm I (temozolomide, olaparib)
    2. Arm II (temozolomide)
    description
    Given PO
    name
    Temozolomide
    other Names
    1. CCRG-81045
    2. Gliotem
    3. Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-
    4. M & B 39831
    5. M and B 39831
    6. Methazolastone
    7. RP-46161
    8. SCH 52365
    9. Temcad
    10. Temizole
    11. Temodal
    12. Temodar
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
46
type
ESTIMATED
Registered outcome plans (not posted results)
other Outcomes
  1. description
    Levels of chromogranin A, urine and/or plasma catecholamines and metanephrines may predict response to therapy. The proportion of patients with a biochemical response of partial response or better, as determined by plasma and/or urine catecholamines and metanephrines, will be calculated, and a 95% confidence interval will be placed on this proportion. For each factor, we will calculate the mean +/- standard deviation, minimum, maximum, and quartiles; in addition, we will generate box and whisker plot.
    measure
    Biochemical response
    time Frame
    Up to 5 years
  2. description
    Will analyze for methyltransferase (MGMT) methylation expression in archival tumors and correlate with the radiographic response rate in metastatic pheochromocytoma/paraganglioma. This is hypothesis generated box and whisker plot.
    measure
    Biomolecular markers associated with clinical outcome
    time Frame
    Up to 5 years
primary Outcomes
  1. description
    Will be compared between treatment arms using the un-stratified log-rank test at one-sided level of 0.11 and the p-value will be used for decision making. The hazard ratio will be estimated using a Cox proportional hazards model and the 95% confidence interval for the hazard ratio will be provided. Results from a stratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer-Crowley methodology will be used to construct the 95% confidence interval for the median PFS for each treatment arm.
    measure
    Progression-free survival (PFS)
    time Frame
    From randomization to the first documentation of disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) or death, assessed up to 5 years
secondary Outcomes
  1. description
    Patients who are alive will be censored at last follow-up. The distribution of survival time will be estimated using the method of Kaplan-Meier. OS will be compared between treatment arms using the log-rank test. OS medians, survival rates and hazard ratio will be estimated along with 95% confidence intervals.
    measure
    Overall survival (OS)
    time Frame
    From randomization to death due to any cause, assessed up to 5 years
  2. description
    Will be assessed by RECIST version 1.1 criteria. Will be estimated using objective response rate where objective response rate is defined as the number of evaluable patients achieving a response (partial response or complete response per RECIST version 1.1) during treatment with study therapy divided by the total number of evaluable patients. Rates of response will be compared across arms using a Chi-Square Test for Proportion. Point estimates will be generated for objective response rates within each arm along with 95% binomial confidence intervals.
    measure
    Objective response
    time Frame
    Up to 5 years
  3. description
    Will be assessed per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The term toxicity is defined as adverse events that are classified as possibly, probably, or definitely related to study treatment. Toxicities will be evaluated via the ordinal Common Terminology Criteria for Adverse Events standard toxicity grading. Similarly, scores (0-4) and the maximum score for each Patient-Reported Outcomes-CTCAE item will be recorded for each patient.
    measure
    Incidence of adverse events
    time Frame
    Up to 5 years
Full study description
brief Summary
This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Poly (adenosine diphosphate \[ADP\]-ribose) polymerases (PARPs) are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib with temozolomide may shrink or stabilize the cancer in patients with pheochromocytoma or paraganglioma better than temozolomide alone.
detailed Description
PRIMARY OBJECTIVE: I. To compare the progression-free survival (PFS) of patients with advanced pheochromocytoma and paraganglioma (APP) receiving temozolomide (dose dense) and olaparib to that of patients receiving temozolomide (pulse dose) alone. SECONDARY OBJECTIVES: I. To compare the overall survival (OS) of patients with APP receiving temozolomide (dose dense) and olaparib versus (vs.) temozolomide (pulse dose) alone. II. To compare the objective response rate (ORR) associated with temozolomide (dose dense) and olaparib vs. temozolomide (pulse dose) alone in patients with APP. III. To evaluate and compare the toxicity profile of temozolomide-based combinations (temozolomide \[dose dense\] and olaparib vs. temozolomide \[pulse dose\]) in patients with APP using Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes (PRO)-CTCAE. OTHER OBJECTIVE: I. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue. EXPLORATORY OBJECTIVES: I. To assess biochemical response: serum catecholamines and metanephrines; urine catecholamines and metanephrines. II. To assess biomolecular markers associated with clinical outcome: germline succinyl dehydrogenase (SDH) mutations and tumor status of the repair enzyme methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT). OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive temozolomide orally (PO) once daily (QD) and olaparib PO twice daily (BID) on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with contrast or magnetic resonance imaging (MRI) throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression. ARM II: Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression. Patients discontinuing treatment due to reasons other than disease progression are followed every 12 weeks until disease progression, then every 6 months until 5 years after registration. Patients discontinuing treatment due to disease progression are followed every 6 months for 5 years after registration.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-53fef25570adf17e4d72
      requested nct id
      NCT04394858
      primary nct id
      NCT04394858
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      7a3a3e3f588e764fa813d59e62485679b825fc0058ca90d25f6e20c915a47f1d
      payload sha256
      6f4f1305bef5a950cd3a605ab20663801ddfad21697c0645322173945ef2f288
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-53fef25570adf17e4d72
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT04394858
      occurrences
      1. context exact
        ate of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 by blinded independent central review.</li><li><strong><a href="/clinicaltrials/NCT04394858">NCT04394858</a></strong> (Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy [Temozolomide] for Advanced Neuroendocrine Cancer)<s
        end
        91086
        exact text
        NCT04394858
        start
        91075
      2. context exact
        tifan per Response Evaluation Criteria in Solid Tumors Version 1.1 by blinded independent central review.</li><li><strong><a href="/clinicaltrials/NCT04394858">NCT04394858</a></strong> (Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy [Temozolomide] for Advanced Neuroendocrine Cancer)<strong>:</stro
        end
        91099
        exact text
        NCT04394858
        start
        91088
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/fc500091dd7dc11d1f.html
      source file sha256
      7a3a3e3f588e764fa813d59e62485679b825fc0058ca90d25f6e20c915a47f1d
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:22:13.440916+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      63374a20cfbb29754188cfbbf664b43a95afc27f05b7dde6cc7445a3679788f4
      source title
      Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: September 9, 2024
        datetime
        2024-09-09T12:00:00Z
        display
        September 9, 2024

    Preserved source evidence · Not medical advice